Page 17 - நிறுவனம் காலாண்டு அறிக்கை ஆன் வடிவம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Chesapeake Utilities Corporation Reports Second Quarter 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Invesco Mortgage Capital Inc Reports Second Quarter 2021 Financial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Chesapeake Utilities Corporation Reports Second Quarter 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Gladstone Investment Corporation Reports Financial Results for its First Quarter Ended June 30, 2021
ACCESSWIRE
MCLEAN, VA / ACCESSWIRE /
August 2, 2021 /Gladstone Investment Corporation (NASDAQ:GAIN) (the Company ) today announced earnings for its first quarter ended June 30, 2021. Please read the Company s Quarterly Report on Form 10-Q, filed today with the U.S. Securities and Exchange Commission (the SEC ), which is available on the SEC s website at
www.sec.gov or the investors section of the Company s website at
(dollars in thousands, except per share data (unaudited)):
Inclusive of $10.3 million, or $0.31 per weighted-average common share, and $3.6 million, or $0.11 per weighted-average common share, of capital gains-based incentive fees accrued during the three months ended June 30, 2021 and March 31, 2021, respectively. These fees were accrued in accordance with United States generally accepted accounting principles ( U.S. GAAP ), where such amounts were not contract
Home / Top News / Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
ANG-3070 was well-tolerated across dose cohorts, achieving drug exposures in humans exceeding exposures in which activity was demonstrated in animal models of proteinuric kidney diseases
Pharmacokinetic data potentially supportive of once-daily dosing
An international Phase 2 trial in patients with primary proteinuric kidney diseases will begin enrolling patients in the second half of this year
Company to host a Virtual Fibrosis R&D Day on September 20, 2021